Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For the now aged CORX folk, AMPA time may be just around the...
Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia
...and so it goes...
Lotta insider / VC selling... usually not a good sign...
SO, how is this not deja vu all over again?
Why would Merck be slow rather than enthused to supply?
The jig may be up...
Since the 1st of the year there has been at least one director resigning with castigating claims of malfeasance, the removal of the CFO & COO, and a notice of financial instruments non-reliance and accounting errors. And not an informative peep from the company.
The employee stock incentive program...
Pierce and Wondering Why....
His departure surely made me wonder why.
BTW, his linked-in page clearly says that he is
"Providing scientific, translational biology and early clinical development expertise to immune-oncology companies, spanning immune-modulatory small molecules, intratumoral gene therapy and therapeutic vaccine approaches."
and that he counts ONCS among his clients.
Pierce... is gone...
This comment you excerpted is over 2 years old.
Oncosec is just one of the organizations for which Pierce now consults.
Surprised you didn't know of these things....
----------------
When Pierce was interviewed just a week ago saying,
Quote:"we’re changing the nature of the game, and I’m amazed that the message hasn’t gotten out. People just don’t know that we’re doing that. I think everyone should be as excited as I am – it’s a brilliant time to be in this field!"
Somee Curiousnes about CSA
A couple potentially complicating and/or compelling informational pieces about CSA.
One is that the prevalence, although something less than 10% of sleep disturbed patients, rises considerably among those having medically significant circumstances, eg. 25-40% of heart failure patients. Thus, the treatment course is not necessarily a single pathway.
Also, the incidence varies almost farcically across national populations... the solution to that puzzle will no doubt be part of a successful treatment.
Post Split 70M shares = 22.75 Billion PreSplit Shares
Just say'n
By whatever name, the CX717 Black Hole that keeps on sucking...
At every glimmer of possibility, the DEEPLY hidden ARTIFACT continues to haunt & quench. For most any neurological professional, Ampakine = necrotic ROT... ask around.
Ah, that it were otherwise...
LOOMING
1 , 4 0 0, 0 0 0, 0 0 0 Authorized shares
total FLOAT
2015 = 4 1 3, 4 7 6, 8 5 3
2014 = 2 3 2, 1 4 5, 3 2 6
chg= 1 8 1, 3 3 1, 5 2 7
total FLOAT 2010
7 8, 9 0 0, 0 0 0
and it seemed a large hill to climb in 2010...
Cannabis- The Good, The Bad And The Ugly... and the...
http://seekingalpha.com/article/2983996-cannabis-the-good-the-bad-and-the-ugly
Summary
GWP and Insys represent potential in "respectable" medical marijuana field.
The recreational marijuana sector is a minefield of dubious plays.
Dichotomy between attitude of the federal government and that of individual states is a negative.
Cancer pain relief could be the biggest revenue potential for cannabinoids.
Recent financial results of GWP and Insys are promising.
1.5 BILLION SHARES!!!????
My, my grandma, what BIG plans you must have.
Please detail... my math must be too fuzzy...
" Name another Biotech that has 30% of its shares owned by institutions..."
What Biotech are you talking about???
Seriously!
ONCS - Best SLAMDUNK since CORT(x)
But, seriously...
Exercise in patients, patience & perfidy...
Ampakines on the Social Network
As an anecdotal FYI from a recent cocktail (non-pharmaceutical) party: Introduced to a fellow identified as a neuroscientist... after much other conversation asked his familiarity with ampakines - "Oh, sure... lots of promise before the induced psychosis..." - a few moments later another fellow joined us, a biochemist who remarked "yes, what a shame about ampa's and the psychotic issues..."
What we have here is a marketing issue.
GPF, properly scaled, the PRAN chart looks an awful lot like COR.....X -- did you do that on purpose?
Apnea Whilst Sleeping...
<Sleep-disordered breathing and the resulting intermittent hypoxia drives obesity, diabetes, hypertension, and neurodegeneration.>
...and Atrial-Fibrillation...
Currently 188K shares at the $.052 bid
First interesting thing to happen here in a while...
Surf.... what?
A giddy crowd, this....
No questions about what happened to Samyang's 14+ Million earlier holdings???
These apparently desperate & mysterious transactions... and did the Court Ordered Confidentiality filing get any notice. Where ARE the conspiratorists here???
Curious....
Results of Phase III Study for Perampanel Presented at 2011 International Epilepsy Congress
www.marketwatch.com/story/results-of-phase-iii...
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. (pub 2/11)
www.ncbi.nlm.nih.gov/pubmed/20977939
Pfizer teams up with University of California for drug discovery
- Can one get from Irvine to San Diego?
www.inpharm.com/news/164317.../
WHAT Artifact? Can someone post the text or a link to FDA's decision?
Hlong, too bad you couldn't have added a dirge mp3 attachment to play with your post.
12:20am $.10 -- Perhaps a new verb... SamYanged?
Ombow makes the very litigable point - the disposition of the highly amped ampa assets
Samyang's got 250k off... so who's holding? GFPnZ, about the 1% - somebody wrote about entertainment... ask Davidal about me & Urko (& a steamy, Farampator blitzed Irvine evening)...
Reality Check: WHY, if anyone believed AMPA modulation had a future, would they invest $1-2M when they buy a controlling interest of all Ampakineland for $5M or less (as Samyang is about to prove)?
SOURCE: Form 4
ISSUER: CORTEX PHARMACEUTICALS INC
SYMBOL: CORX
FILER: SAMYANG OPTICS CO LTD
TITLE: Beneficial Owner
DATE TRANSACTION SHARES PRICE VALUE
5/18/11-5/19/11 Sale 90,100 $0.12 $10,812
Samyang registered exactly 1% of the outstanding shares. And we all know what that means!
Samyang fires a warning shot...
Sold 5/16-5/17 160,000 shares
Total Proposed shares to be sold this registration 788,581
Oh, the ChutzpaH! Voting to amend incentive plan to 30% of shares! Think these guys forgot they are publicly traded????
Paying $625K to very spreadout prez & $100k fees to directors for incredibly lackluster performance.
Public Utilities are supposed to compensated on the size of their assets, not imaging providers.
You may be accurate as to the root of the R+R hostilities, but I have been given to understand there was more at work. It is curious the victim role CORX has had starting during Stoll's time with R+R & FDA... "they" just don't like us...
gfp, you know, the FDA's communications were never shared. The metabolic potential of CX717 overwhelmed anything by any of the dance partners (think Rock&Roll) before or since. ORG's compounds did offer some potential, but "something" has made everyone shed their Ampa portfolios. Elephant, mystery, stigma, whatever... ergo Urko
gfp, perhaps the eerie references obfuscated the point...
There is a mystery, a coffinful of CX717 data pages that have never seen the light of day outside the FDA. Suddenly the wonder-compound of the CNS was tainted & the anticipated indications abandoned... and nobody who should have came around anymore. And, if feels as though, anybody who did drop by, those "interested parties" and "ongoing conversations" have mostly quietly departed.
And... this primary mystery is no doubt linked to the R & R abandonment, don't ya think?
<Elephant> <<What might that be? Maybe we can get some voodoo guy in to do an exorcism :o) >>
gfp, how many V-Men you got??? Clearly the CX717 MYSTERY is a demon... until the postmortem evil lurking within that compound gets ex-pounded, a mushroom cloud hangs... there is something devilish in those missing details... what else could explain the dark aura that prevents ANY suitor from snatching up the priceless Ampakine potential for a pitance?
There is an elephant in the room...
and NOTHING good is going to happen again until that pachyderm is sent packing...
Good News??
corx.OB has shed $200K from the paltry pantry to re-obtain what, after investigation, was deemed unworthy. If not unworthy, then the net value of some eventually marketable RD compound has just been diminished by some amount well North of $15M. If this is Good News....
So the Reverse split is being run up the flagpole... don't forget about the usual carveouts - or perhaps non-dilution is already written into V/S contracts. Yeah...
UBS BVF analyst take on "deal"
[Thoughts on the deal: Very early stage project
Although this deal adds another opportunity in a niche indication for a modest upfront payment, we think this is a high risk deal for Biovail. Cortex tried developing CX717 for other indications (e.g., ADHD and Alzheimer’s disease) with limited success and now believes that it may work in respiratory depression.
It is too early for us to get excited about this drug. The IV formulation has not yet been developed and we will need to see some proof-of-concept data with the IV formulation before we can give some credit to this drug.]
<<Pardon,...exponentiate?>>
BIG BUCKS!, yeah...
"<<This is a big vote of confidence>>
"<<and I think CORX is finally heading in the right direction.>>"
Seems that this is an absolutely HUGE vote of confidence, but, very importantly not for CORX but for expanding the general notion that ampakines may actually have a functional medical future. This purchase should exponentiate the intellectual property prospects of the remaining applications.